很少有研究描述儿童室管膜瘤幸存者的迟发效应负担。为了解决这一差距，我们使用基于人群的室管膜瘤幸存者队列中的真实世界健康服务数据检查了这些后遗症。1987 年至 2015 年间在加拿大安大略省被诊断患有室管膜瘤的所有 18 岁以下且存活至少 5 年的个体将他们最新的儿科癌症事件（索引日期）与人群对照进行 1:5 匹配。与省级卫生服务数据联系后，比较了幸存者和对照组之间多种医疗和功能结果的累积发生率。在 96 名幸存者中，77.1% 接受过放射治疗，9.4% 接受过顺铂治疗。指数后 10 年，幸存者全因死亡的风险显着升高（7.1%，95% 置信区间 [CI]：1.0-13.3 对比 0.3%，95% CI：0.0-1.0；p = .0002 ）、非产科住院（45.1%，95% CI：32.6-56.7 对比 10.6%，95% CI：7.6-14.1；p < .0001）、中风（6.5%，95% CI：2.3-13.7 对比0%；p < .0001），需要扩音设备的严重听力损失（7.5%，95% CI：2.7-15.7 对比 0%；p < .0001），接受家庭护理服务（27.6%，95% CI：18.5） -37.5 vs. 7.7%, 95% CI: 5.3-10.7；p < 0.0001），并提交残疾支持处方索赔（24.0%, 95% CI: 14.8-34.3 vs. 5.4%, 95% CI: 3.5- 7.8；p < .0001) 与对照组相比。小儿室管膜瘤幸存者极易出现严重的晚期后遗症，包括死亡、中风、严重听力损失和残疾。需要紧急努力改进风险分层方法，以减少低风险疾病儿童接触有毒治疗的情况。预防或降低发生晚期后遗症风险的干预措施对于优化幸存者长期健康至关重要。© 2024 作者。儿科血液

Few studies have characterized the burden of late effects among childhood ependymoma survivors. To address this gap, we examined these sequelae using real-world health services data in a population-based ependymoma survivor cohort.All individuals younger than 18 years diagnosed with an ependymoma in Ontario, Canada between 1987 and 2015 who had survived at least 5 years from their latest pediatric cancer event (index date) were matched 1:5 with population controls. Following linkage with provincial health services data, the cumulative incidences of multiple medical and functional outcomes between survivors and controls were compared.Among 96 survivors, 77.1% had been irradiated and 9.4% had received cisplatin. At 10 years post-index, survivors were at significantly higher risk of all-cause mortality (7.1%, 95% confidence interval [CI]: 1.0-13.3 vs. 0.3%, 95% CI: 0.0-1.0; p = .0002), non-obstetric hospitalization (45.1%, 95% CI: 32.6-56.7 vs. 10.6%, 95% CI: 7.6-14.1; p < .0001), stroke (6.5%, 95% CI: 2.3-13.7 vs. 0%; p < .0001), severe hearing loss requiring an amplification device (7.5%, 95% CI: 2.7-15.7 vs. 0%; p < .0001), receiving homecare service (27.6%, 95% CI: 18.5-37.5 vs. 7.7%, 95% CI: 5.3-10.7; p < .0001), and submitting a disability support prescription claim (24.0%, 95% CI: 14.8-34.3 vs. 5.4%, 95% CI: 3.5-7.8; p < .0001) compared to controls.Pediatric ependymoma survivors are highly vulnerable to severe late sequelae, including death, stroke, severe hearing loss, and disability. Urgent efforts are needed to improve risk-stratification approaches that mitigate exposure to toxic therapies for children with lower risk disease. Interventions to prevent or decrease the risk of developing late sequelae are critical to optimizing survivor long-term health.© 2024 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.